Galapagos is a Belgian biotechnology company headquartered in Mechelen and founded in 1999, listed on Euronext Brussels and Nasdaq.
After its filgotinib JAK inhibitor underperformed in the United States and its Gilead partnership unwound, Galapagos went through a difficult period and a major reorganisation, and is now pivoting toward oncology CAR-T cell therapy.